Canada Atopic Dermatitis Drugs Market Size & Outlook
Global Market
Related Markets
Canada atopic dermatitis drugs market highlights
- The Canada atopic dermatitis drugs market generated a revenue of USD 1,053.3 million in 2025 and is expected to reach USD 1,855.2 million by 2033.
- The Canada market is expected to grow at a CAGR of 7.2% from 2026 to 2033.
- In terms of segment, biologics was the largest revenue generating drug class in 2025.
- PDE4 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Atopic dermatitis drugs market data book summary
| Market revenue in 2025 | USD 1,053.3 million |
| Market revenue in 2033 | USD 1,855.2 million |
| Growth rate | 7.2% (CAGR from 2026 to 2033) |
| Largest segment | Biologics |
| Fastest growing segment | PDE4 Inhibitors |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics |
| Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
Other key industry trends
- In terms of revenue, Canada accounted for 5.4% of the global atopic dermatitis drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. atopic dermatitis drugs market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 1,177.5 million by 2033.
Canada is a rapidly developing market for atopic dermatitis. High prevalence of the disease and increasing consumer awareness in the country are expected to further boost the market. Atopic dermatitis affects 17% of the population at least once per lifetime.
This creates a large patient pool for prescription of atopic dermatitis drugs. The Eczema Society of Canada works to facilitate the treatment of eczema and atopic dermatitis patients. Furthermore, November is celebrated in Canada as Eczema Awareness Month, which aims to raise awareness about the disease and related conditions.
In November 2018, Pfizer announced the availability of EUCRISA (crisaborole) in Canada, intended to ease the treatment of atopic dermatitis patients. Novel biologic drug DUPIXENT by Sanofi was approved by Health Canada in September 2019, making it the first biologic drug approved for atopic dermatitis.
No credit card required*
Publish Date: Jun 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Atopic Dermatitis Drugs Market Scope
Atopic Dermatitis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Otsuka Holdings Co Ltd | View profile | 39,548 | 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, Japan, 101-0048 | www.otsuka.com/jp |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Galderma Group AG Registered Shares | View profile | - | Zählerweg 10, Zug, Switzerland, 6300 | www.galderma.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Regeneron Pharmaceuticals Inc | View profile | 13,450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | www.regeneron.com |
| Incyte Corp | View profile | 2,524 | 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 | www.incyte.com |
| LEO Pharma | View profile | 1001-5000 | Parsippany, New Jersey, United States, North America | www.leo-pharma.us/ |
Canada Atopic Dermatitis Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Atopic Dermatitis Drugs Market Outlook will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 47.44% in 2025.
Horizon Databook has segmented the Canada atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2021 to 2033.
Canada is a rapidly developing market for atopic dermatitis. High prevalence of the disease and increasing consumer awareness in the country are expected to further boost the market. Atopic dermatitis affects 17% of the population at least once per lifetime.
This creates a large patient pool for prescription of atopic dermatitis drugs. The Eczema Society of Canada works to facilitate the treatment of eczema and atopic dermatitis patients. Furthermore, November is celebrated in Canada as Eczema Awareness Month, which aims to raise awareness about the disease and related conditions.
In November 2018, Pfizer announced the availability of EUCRISA (crisaborole) in Canada, intended to ease the treatment of atopic dermatitis patients. Novel biologic drug DUPIXENT by Sanofi was approved by Health Canada in September 2019, making it the first biologic drug approved for atopic dermatitis.
- Canada Atopic Dermatitis Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Corticosteroids
- Calcineurin Inhibitors
- PDE4 Inhibitors
- Biologics
- Others
- Canada Atopic Dermatitis Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Topical
- Parenteral
- Oral
- Canada Atopic Dermatitis Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Reasons to subscribe to Atopic Dermatitis Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Atopic Dermatitis Drugs Market Outlook databook
- Our clientele includes a mix of Atopic Dermatitis Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Atopic Dermatitis Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Atopic Dermatitis Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Canada Atopic Dermatitis Drugs Market, 2021-2033 (US$M)
Canada Drug Class - Atopic Dermatitis Drugs Market Statistics, 2025 - 2033 (US$M)
